新闻
BPMC
--
0.00%
--
骨增生性纤维增生症(FOP)-Pipeline Insight,2020年
Feb 26, 2021 (Heraldkeepers) -- DelveInsight's, "Fibrodysplasia Ossificans Progressiva (FOP) - Pipeline Insight, 2020," report provides comprehensive...
Heraldkeepers · 6天前
成纤维细胞生长因子受体4市场规模,增长,全球2021年份额,趋势,全球行业主要参与者,到2026年的区域预测
Feb 22, 2021 (The Expresswire) -- Global Fibroblast Growth Factor Receptor 4 Market 2021 industry research report gives Advancement strategies and plans are...
The Express Wire · 02/23 04:49
胃肠道间质瘤(GIST)药物市场规模,份额,预测增长2021年,全球组织,顶级供应商,行业研究,市场和最终用户到2026年
Feb 22, 2021 (The Expresswire) -- Global Gastrointestinal Stromal Tumor (GIST) Drug Market 2021 industry research report gives Advancement strategies and...
The Express Wire · 02/23 04:49
分析师看好顶级保健股:蓝图药物(BPMC),精确科学(EXAS)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Blueprint Medicines (BPMC), Exact Sciences (EXAS) and
SmarterAnalyst · 02/19 09:04
全球成纤维细胞生长因子受体4的市场规模2021-2026,其中主要国家/地区数据行业价格趋势,规模估计,业务增长,报告最新研究,业务分析和预测分析研究|使用Covid 19 Analysis
Feb 19, 2021 (The Expresswire) -- “Fibroblast Growth Factor Receptor 4 Market” Report (2021-2026) offers a learned and top to bottom investigation on the...
The Express Wire · 02/19 05:13
分析师提供有关医疗保健公司的见解:蓝图药物(BPMC),亨利·舍因(HSIC)和免疫药(IMVT)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Blueprint Medicines (BPMC), Henry Schein (HSIC) and
SmarterAnalyst · 02/18 17:55
每日生物技术动向:Lily-Rigel许可交易,vTv开始早期银屑病研究,免疫数据读取
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17)
Benzinga · 02/18 13:14
摩根士丹利(Morgan Stanley)维持蓝图药物的均等评级,将目标价格下调至105美元
Morgan Stanley analyst David Lebowitz maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and lowers the price target from $112 to $105.
Benzinga · 02/18 13:04
分析家的首选医疗保健:蓝图药物(BPMC),CureVac(CVAC)
SmarterAnalyst · 02/18 11:15
分析师看好顶级保健股:蓝图药物(BPMC),ANI制药(ANIP)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Blueprint Medicines (BPMC), ANI Pharmaceuticals (ANIP) and
SmarterAnalyst · 02/17 21:45
10-K:BLUEPRINT MEDICAINES CORP
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 02/17 21:40
8-K:Blueprint Medicines Corp
(EDGAR Online via COMTEX) -- 0001597264false00015972642021-02-172021-02-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/17 13:16
Blueprint Medicines Q4每股收益($ 1.53)超过$(1.62)估计,销售额$ 34.11M超过$ 29.24M估计
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(1.62) by 5.56 percent. This is a 13.33 percent decrease over losses of $(1.35) per share
Benzinga · 02/17 12:14
胃肠道癌药物市场分析2021,按区域和大小,份额,增长,前景,具有产品概况的主要参与者,规格| COVID-19的影响,到2025年的预测
The Express Wire · 02/17 08:07
胆管癌药物市场2021:按行业,规模,成本结构和主要参与者分析的深度分析2027研究报告| Business Wire行业研究部
The Express Wire · 02/16 07:01
骨增生性纤维增生症药物市场2021年发展趋势,细分,毛利率,需求,行业状况,战略和主要参与者分析及区域预测2027
The Express Wire · 02/16 07:01
胃肠道间质瘤(GIST)药物市场2021年全球地区的增长趋势,包括行业分析,增长规模,份额,类型,应用,发展战略和到2027年的预测
The Express Wire · 02/15 05:15
系统性红细胞增多症治疗市场2021年行业增长估计,主要参与者分析,毛利率,策略,应用,投资计划,机会和2027年预测
Feb 15, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Systemic Mastocytosis...
The Express Wire · 02/15 05:14
生物技术的一周提前:FDA关于G1治疗药物的决定,轻日历周收入的混合
Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap earnings, multiple conference presentations, data readouts and a slew of IPOs were all part of the week's news flow.
Benzinga · 02/14 13:10
全球骨增生性纤维增生药物市场规模,分析,细分,竞争对手,竞争对手,市场份额,增长预测研究报告
Feb 10, 2021 (The Expresswire) -- “Global Fibrodysplasia Ossificans Progressiva Drug Market" Forecast 2021-2026 report supports to increase economies with...
The Express Wire · 02/10 11:09
微牛提供丰富的实时BPMC股票新闻,让你可以通过多个平台了解BPMC股票行情最新动态,这些免费的蓝图医药新闻可以帮助你做出明智投资。
BPMC 简况
Blueprint Medicines Corporation是一家生物制药公司。该公司专注于由异常激酶激活引起的遗传病患者。该公司专注于生产具有治疗窗口的候选药品,为没有足够治疗选择的患者提供临床药物。该公司在癌症和遗传性疾病方面开发了小分子药物。该公司的候选药物,BLU-285靶向KIT外显子17突变体和PDGFRa D842V,它们是异常活性的受体酪氨酸激酶突变体,是癌症和增殖性疾病的驱动因子。该公司为患有系统性肥大细胞增多症(SM)、肥大细胞骨髓增值性疾病和患有胃肠道间质瘤(GIST)患者亚组的患者开发BLU-285。其候选药物,BLU-554靶向FGFR4。FGFR4为一种激酶,被异常激活并且是肝细胞癌(HCC)患者亚群疾病的激活者。